US Moves Medical Cannabis to Schedule III in Historic Policy Shift

WASHINGTON, D.C. – April 23, 2026 – In a seismic shift in federal drug policy, the U.S. Department of Justice and the Drug Enforcement Administration have issued a final order reclassifying certain marijuana products from Schedule I to Schedule III of the Controlled Substances Act. The move, effective April 22, 2026, represents the most significant federal cannabis reform in over 50 years, formally acknowledging the substance's medical value and setting the stage for profound changes in patient care, scientific research, and the cannabis industry.

The American Council of Cannabis Medicine (ACCM), a leading industry advocacy group, immediately applauded the decision. "This is a pivotal moment for patients, providers, and the broader healthcare system," said Mike Butler, Co-Chair of the ACCM Outreach Committee. "Rescheduling to Schedule III validates the growing body of scientific and clinical evidence supporting medical cannabis while enabling the next phase of responsible integration into mainstream care."

A Landmark Shift in Federal Policy

For decades, marijuana has been federally classified as a Schedule I substance, a category reserved for drugs with no currently accepted medical use and a high potential for abuse, placing it alongside heroin and LSD. The new order moves specific cannabis products to Schedule III, which includes substances with a currently accepted medical use, such as Tylenol with codeine and testosterone. This reclassification, however, is not a blanket legalization.

The order applies specifically to two categories: FDA-approved drugs containing marijuana and marijuana products distributed for medical purposes under a valid state-issued license. This means that recreational cannabis, even in states where it is legal, remains a Schedule I substance under federal law, as do unlicensed cannabis activities and synthetically derived THC products.

Acting Attorney General Todd Blanche issued the scheduling order under a provision that allows for expedited action to satisfy U.S. obligations under international drug treaties, bypassing the typical lengthy rulemaking process. This decisive action aligns federal policy more closely with the 38 states that have already established their own medical cannabis programs, which serve millions of American patients.

From Stigma to Science: Unlocking Research and Patient Care

The reclassification is expected to dismantle decades-old barriers that have stifled critical medical research. Operating under Schedule I required researchers to navigate a gauntlet of stringent security protocols and administrative hurdles, severely limiting scientific inquiry into cannabis's therapeutic potential. As a Schedule III substance, medical marijuana will be subject to less restrictive regulations, making it easier for scientists to obtain the substance for study and conduct clinical trials.

"Rescheduling cannabis to Schedule III is a long-overdue step that opens the door to real science," stated Dr. Annabelle Manalo-Morgan, ACCM Research Committee Chairman. "For years, researchers have been blocked from studying its full therapeutic potential. Now, we can generate the data, educate responsibly, and ensure that access is guided by evidence — not stigma."

For patients, this shift promises to expand access and legitimize cannabis as a medical treatment. Physicians will now be able to legally prescribe the rescheduled cannabis products, a stark contrast to the previous framework where they could only "recommend" it. This change is expected to encourage more healthcare providers to engage in patient-centered cannabis care and could pave the way for future inclusion in insurance and wellness programs, though that remains a future goal.

The Economic Green Light for Industry

Perhaps the most immediate and dramatic impact will be felt by state-licensed medical cannabis businesses, which will now be freed from the crushing weight of Internal Revenue Code Section 280E. This tax provision has long prohibited businesses trafficking in Schedule I or II substances from deducting ordinary business expenses like rent, payroll, and utilities.

With medical cannabis moving to Schedule III, Section 280E will no longer apply to compliant operators. This change is expected to inject billions of dollars back into the industry, allowing companies to reinvest in product quality, innovation, patient care, and staff. The Treasury and IRS have announced they will provide further guidance, including a transition rule that would likely apply the tax relief for the full taxable year.

However, ambiguity remains for businesses that serve both medical and recreational markets. The tax relief does not extend to recreational sales, creating complex accounting challenges that will require clear regulatory guidance. The DOJ's order also establishes an expedited federal registration pathway for state-licensed medical marijuana entities, aiming to better integrate the existing state-level frameworks with federal oversight.

The Road Ahead: Navigating a New Federal Landscape

While advocates celebrate the historic decision, many emphasize that it is a foundational step, not the final destination for cannabis reform. The ACCM noted that this action is "not an endpoint, but a foundation for continued progress." Many other advocacy groups, while welcoming the move, continue to push for the complete removal of cannabis from the Controlled Substances Act, arguing that a state-regulated model similar to alcohol is the ultimate goal.

The DEA has also announced it will begin a new administrative hearing process on June 29, 2026, to consider the broader rescheduling of all marijuana, which could lead to further policy evolution. The immediate reclassification also opens the door for DEA-registered medical cannabis operators to potentially access international markets, though this will be subject to complex import/export regulations designed to comply with international treaties.

Legal and regulatory questions will continue to surface as federal agencies, states, businesses, and healthcare providers adapt to this new reality. The interaction between federal and state law, workplace drug testing policies, and the potential for legal challenges to the Acting Attorney General's authority will shape the next chapter of cannabis policy in America. For now, the move to Schedule III marks a definitive turning point, shifting the federal government's stance from prohibition to recognition of medical value.